Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

resmed inc. - RMD

RMD

Close Chg Chg %
222.87 1.23 0.55%

Closed Market

224.10

+1.23 (0.55%)

Volume: 642.89K

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Trade Now

Company Overview: resmed inc. - RMD

RMD Key Data

Open

$221.15

 Day Range

219.01 - 226.26

52 Week Range

199.92 - 293.75

 Market Cap

$32.64B

Shares Outstanding

145.68M

 Public Float

144.74M

Beta

0.93

 Rev. Per Employee

N/A

P/E Ratio

22.15

 EPS

$10.16

Yield

103.98%

 Dividend

$0.60

EX-DIVIDEND DATE

Feb 12, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.05M

  

RMD Performance

1 Week
 
 1.64%
 
1 Month
 
 -11.38%
 
3 Months
 
 -8.46%
 
1 Year
 
 9.22%
 
5 Years
 
 15.25%
 

RMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About resmed inc. - RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

RMD At a Glance

ResMed, Inc.
9001 Spectrum Center Boulevard
San Diego, California 92123
Phone 1-858-836-5000 Revenue 5.15B
Industry Medical Specialties Net Income 1.40B
Sector Health Technology 2025 Sales Growth 9.84%
Fiscal Year-end 06 / 2026 Employees 10,600
View SEC Filings

RMD Valuation

P/E Current 22.151
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 27.139
Price to Sales Ratio 7.387
Price to Book Ratio 6.328
Price to Cash Flow Ratio 21.70
Enterprise Value to EBITDA 19.573
Enterprise Value to Sales 7.315
Total Debt to Enterprise Value 0.023

RMD Efficiency

Revenue/Employee 485,502.547
Income Per Employee 132,143.679
Receivables Turnover 5.195
Total Asset Turnover 0.684

RMD Liquidity

Current Ratio 3.44
Quick Ratio 2.53
Cash Ratio 1.20

RMD Profitability

Gross Margin 58.482
Operating Margin 32.788
Pretax Margin 32.597
Net Margin 27.218
Return on Assets 18.618
Return on Equity 25.863
Return on Total Capital 20.539
Return on Invested Capital 22.444

RMD Capital Structure

Total Debt to Total Equity 14.273
Total Debt to Total Capital 12.491
Total Debt to Total Assets 10.421
Long-Term Debt to Equity 13.596
Long-Term Debt to Total Capital 11.898
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Resmed Inc. - RMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.58B 4.22B 4.69B 5.15B
Sales Growth
+11.93% +18.02% +10.95% +9.84%
Cost of Goods Sold (COGS) incl D&A
1.58B 1.91B 2.08B 2.14B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
193.84M 196.52M 216.21M 235.81M
Depreciation
162.76M 117.11M 129.13M 150.22M
Amortization of Intangibles
31.08M 79.42M 87.08M 85.59M
COGS Growth
+14.12% +20.47% +8.76% +2.89%
Gross Income
1.99B 2.31B 2.61B 3.01B
Gross Income Growth
+10.24% +16.07% +12.76% +15.37%
Gross Profit Margin
+55.71% +54.79% +55.68% +58.48%
2022 2023 2024 2025 5-year trend
SG&A Expense
992.95M 1.16B 1.22B 1.32B
Research & Development
253.57M 287.64M 307.52M 331.28M
Other SG&A
739.37M 874.00M 917.14M 991.02M
SGA Growth
+10.86% +16.99% +5.42% +7.97%
Other Operating Expense
- - - -
-
Unusual Expense
- (9.13M) 54.03M (7.60M)
EBIT after Unusual Expense
1.00B 1.16B 1.33B 1.69B
Non Operating Income/Expense
(17.49M) 1.15M (5.24M) (4.82M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
(8.49M) (7.26M) (1.85M) 3.64M
Interest Expense
22.31M 60.62M 60.05M 12.61M
Interest Expense Growth
-6.99% +171.67% -0.92% -79.00%
Gross Interest Expense
22.31M 60.62M 60.05M 12.61M
Interest Capitalized
- - - -
-
Pretax Income
960.48M 1.10B 1.26B 1.68B
Pretax Income Growth
+8.69% +14.70% +14.81% +32.64%
Pretax Margin
+26.84% +26.09% +27.00% +32.60%
Income Tax
181.05M 204.11M 243.85M 276.84M
Income Tax - Current - Domestic
15.08M 50.77M 74.35M 39.66M
Income Tax - Current - Foreign
177.79M 198.77M 219.37M 298.17M
Income Tax - Deferred - Domestic
(15.38M) (24.11M) (27.55M) (6.93M)
Income Tax - Deferred - Foreign
3.57M (21.32M) (22.33M) (54.06M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(8.49M) (7.26M) (1.85M) 3.64M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
779.44M 897.56M 1.02B 1.40B
Minority Interest Expense
- - - -
-
Net Income
779.44M 897.56M 1.02B 1.40B
Net Income Growth
+64.26% +15.15% +13.75% +37.20%
Net Margin Growth
+21.78% +21.25% +21.79% +27.22%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
779.44M 897.56M 1.02B 1.40B
Preferred Dividends
- - - -
-
Net Income Available to Common
779.44M 897.56M 1.02B 1.40B
EPS (Basic)
5.3362 6.1156 6.9442 9.5472
EPS (Basic) Growth
+63.42% +14.61% +13.55% +37.48%
Basic Shares Outstanding
146.07M 146.76M 147.02M 146.72M
EPS (Diluted)
5.3007 6.087 6.9194 9.5067
EPS (Diluted) Growth
+63.60% +14.83% +13.68% +37.39%
Diluted Shares Outstanding
147.04M 147.46M 147.55M 147.34M
EBITDA
1.19B 1.35B 1.60B 1.92B
EBITDA Growth
+8.18% +12.93% +18.67% +20.18%
EBITDA Margin
+33.37% +31.93% +34.16% +37.37%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 307.946
Number of Ratings 29 Current Quarters Estimate 2.90
FY Report Date 06 / 2026 Current Year's Estimate 11.054
Last Quarter’s Earnings 2.81 Median PE on CY Estimate N/A
Year Ago Earnings 9.55 Next Fiscal Year Estimate 12.274
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 11 24 24
Mean Estimate 2.90 2.88 11.05 12.27
High Estimates 3.00 3.00 11.30 12.89
Low Estimate 2.83 2.82 10.35 11.87
Coefficient of Variance 1.52 1.89 1.58 2.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 14
OVERWEIGHT 6 6 6
HOLD 8 8 8
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Resmed Inc. - RMD

Date Name Shares Transaction Value
Mar 6, 2026 Peter C. Farrell Director 62,773 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.22 per share 16,334,790.06
Feb 11, 2026 Michael J. Farrell Chairman and CEO; Director 471,214 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $146.34 per share 68,957,456.76
Feb 11, 2026 Michael J. Farrell Chairman and CEO; Director 466,223 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $273.78 per share 127,642,532.94
Feb 11, 2026 Michael J. Farrell Chairman and CEO; Director 44,921 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 25, 2025 Nicole Mowad-Nassar Director 777 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 25, 2025 John B. Hernandez Director 5,118 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2025 Brett A. Sandercock Chief Financial Officer 88,745 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2025 Justin G. Leong Chief Product Officer 27,180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2025 John B. Hernandez Director 4,045 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $287.1 per share 1,161,319.50
Aug 20, 2025 John B. Hernandez Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2025 Michael Rider Global General Counsel 11,427 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2025 Michael Rider Global General Counsel 8,603 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $244.79 per share 2,105,928.37

Resmed Inc. in the News